Robert Bessler Sells 79,630 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 79,630 shares of LifeStance Health Group stock in a transaction on Friday, December 12th. The stock was sold at an average price of $7.01, for a total value of $558,206.30. Following the sale, the director directly owned 1,382,175 shares of the company’s stock, valued at $9,689,046.75. This represents a 5.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $86,597.00.

LifeStance Health Group Price Performance

Shares of LifeStance Health Group stock opened at $6.91 on Thursday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $2.69 billion, a price-to-earnings ratio of -230.33 and a beta of 1.13. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $8.30. The company has a 50-day simple moving average of $5.92 and a two-hundred day simple moving average of $5.35.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The firm had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. During the same quarter in the prior year, the business posted ($0.02) EPS. The business’s revenue was up 16.3% compared to the same quarter last year. Analysts forecast that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Analyst Ratings Changes

LFST has been the subject of several analyst reports. Wall Street Zen cut LifeStance Health Group from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Barclays assumed coverage on LifeStance Health Group in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday. BTIG Research boosted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Finally, Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. increased its stake in shares of LifeStance Health Group by 1.4% in the first quarter. Invesco Ltd. now owns 164,384 shares of the company’s stock valued at $1,095,000 after buying an additional 2,238 shares during the period. Vident Advisory LLC boosted its holdings in LifeStance Health Group by 12.7% in the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after acquiring an additional 2,447 shares during the last quarter. State of Wyoming increased its position in LifeStance Health Group by 3.8% during the 3rd quarter. State of Wyoming now owns 89,927 shares of the company’s stock valued at $495,000 after purchasing an additional 3,298 shares during the period. Legal & General Group Plc increased its position in LifeStance Health Group by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 144,263 shares of the company’s stock valued at $746,000 after purchasing an additional 3,331 shares during the period. Finally, Polar Capital Holdings Plc raised its holdings in LifeStance Health Group by 19.3% during the 3rd quarter. Polar Capital Holdings Plc now owns 21,775 shares of the company’s stock worth $120,000 after purchasing an additional 3,525 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.